A
10.36
0.38 (3.81%)
| Previous Close | 9.98 |
| Open | 9.95 |
| Volume | 497,758 |
| Avg. Volume (3M) | 593,496 |
| Market Cap | 427,012,096 |
| Price / Earnings (Forward) | 96.15 |
| Price / Sales | 1.41 |
| Price / Book | 2.47 |
| 52 Weeks Range | |
| Earnings Date | 2 Apr 2026 |
| Profit Margin | -11.62% |
| Operating Margin (TTM) | -4.53% |
| Diluted EPS (TTM) | -0.830 |
| Quarterly Revenue Growth (YOY) | 12.90% |
| Total Debt/Equity (MRQ) | 5.54% |
| Current Ratio (MRQ) | 2.21 |
| Operating Cash Flow (TTM) | -10.13 M |
| Levered Free Cash Flow (TTM) | 2.21 M |
| Return on Assets (TTM) | -5.03% |
| Return on Equity (TTM) | -17.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | AngioDynamics, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.8
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Value |
| % Held by Insiders | 6.84% |
| % Held by Institutions | 92.87% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Weber Capital Management Llc /Adv | 31 Dec 2025 | 1,400,149 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care |
| 03 Feb 2026 | Announcement | AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance |
| 06 Jan 2026 | Announcement | AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability |
| 23 Dec 2025 | Announcement | AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026 |
| 22 Dec 2025 | Announcement | AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |